Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.49 USD
−17.19 M USD
0.00 USD
4.94 M
About Brainstorm Cell Therapeutics Inc.
Sector
Industry
CEO
Chaim Lebovits
Website
Headquarters
New York
Founded
2000
FIGI
BBG000FR6HQ1
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
BCLI Brainstorm Cell Therapeutics Options Ahead Of EarningsLooking at the BCLI Brainstorm Cell Therapeutics options chain ahead of earnings , I would buy the $2 strike price Calls with
2023-8-18 expiration date for about
$0.50 premium.
If the options turn out to be profitable Before the earnings release, I would sell at least 50%.
Looking forward to read y
Brainstorm Cell Therapeutics Storming up a dive. BCLIFrequent pattern by now. Flat in C Wave completion. Here we go.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, ar
BCLI target price at $6, +73%BCLI has activated a falling wedge pattern with potential target to $6 that is +73% from current price
BCLI - Long Setup Buying around $13 in July last year. Break above 4.16, Stop signal 3.63. Target 4.93, Target 2 5.93. August $4.00 call options are 0.60. November $5.00 Call options are 0.75.
Long | BCLI | Earning day | >10% P NASDAQ:BCLI
Possible Scenario: LONG
Evidence: Price Action
Call options, Strike 4$, 05/21/21
Call options, Strike 5$, 05/21/21
*It's ready to fly.
This is my idea and could be wrong 100%,
BCLI LongDemand Zone
RSI Divergence
MACD Divergence
Williams %R oversold
OBV is above SMA34
Entry 3.65
Stop 2.8
Target1 8
Target2 12
I am not a PRO trader. I trade option to test my trading plan with small cost.
The max Risk of each plan is less than 1% of my account.
If you like this idea, please use SI
BCLI Technical Analysis 🧙Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's d
BCLI target price at $6.35 +24%Brainstorm Cell Therapeutics has activated a falling wedge with price target at $6.35 +24% from current price and also deactivated a second bearish impulse.
Possible +50% playRecently got smashed down to very low levels, could see a reversal to $8, and from then on to $10
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BCLI is 2.23 USD — it has decreased by −9.21% in the past 24 hours. Watch Brainstorm Cell Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Brainstorm Cell Therapeutics Inc. stocks are traded under the ticker BCLI.
BCLI stock has risen by 41.78% compared to the previous week, the month change is a 69.67% rise, over the last year Brainstorm Cell Therapeutics Inc. has showed a −22.97% decrease.
We've gathered analysts' opinions on Brainstorm Cell Therapeutics Inc. future price: according to them, BCLI price has a max estimate of 10.00 USD and a min estimate of 10.00 USD. Watch BCLI chart and read a more detailed Brainstorm Cell Therapeutics Inc. stock forecast: see what analysts think of Brainstorm Cell Therapeutics Inc. and suggest that you do with its stocks.
BCLI reached its all-time high on Jan 7, 2005 with the price of 787.11 USD, and its all-time low was 1.05 USD and was reached on Nov 14, 2024. View more price dynamics on BCLI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BCLI stock is 7.66% volatile and has beta coefficient of 2.02. Track Brainstorm Cell Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Brainstorm Cell Therapeutics Inc. there?
Today Brainstorm Cell Therapeutics Inc. has the market capitalization of 11.81 M, it has increased by 15.64% over the last week.
Yes, you can track Brainstorm Cell Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Brainstorm Cell Therapeutics Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
BCLI earnings for the last quarter are −0.51 USD per share, whereas the estimation was −0.57 USD resulting in a 11.30% surprise. The estimated earnings for the next quarter are −0.27 USD per share. See more details about Brainstorm Cell Therapeutics Inc. earnings.
Brainstorm Cell Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
BCLI net income for the last quarter is −2.71 M USD, while the quarter before that showed −2.54 M USD of net income which accounts for −6.57% change. Track more Brainstorm Cell Therapeutics Inc. financial stats to get the full picture.
No, BCLI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 29.00 employees. See our rating of the largest employees — is Brainstorm Cell Therapeutics Inc. on this list?
Like other stocks, BCLI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Brainstorm Cell Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Brainstorm Cell Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Brainstorm Cell Therapeutics Inc. stock shows the sell signal. See more of Brainstorm Cell Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.